Bharat Biotech: News, Photos, Latest News Headlines about Bharat Biotech

Bharat Biotech completes clinical trials for intranasal Covid vaccine

August 17, 2022 6:59 am

The BBV154 intranasal Covid vaccine has proven to be safe, well-tolerated, and immunogenic in subjects in controlled clinical trials, the company said.

Krishna Ella, Bharat Biotech, Covid, Covid-19, Covid vaccine, Covid-19 vaccine, vaccination, jabs, shots, coronavirus, coronavirus vaccine, covid variant, Indian Express, India news, current affairs, Indian Express News Service, Express News Service, Express News, Indian Express India News

‘New variant of Covid likely by November, may evade vaccine’, says Krishna Ella

July 31, 2022 7:09 am

Phase 3 trial for BB’s nasal vaccine was announced as completed in June this year and the company is yet to submit the trial data with the DCGI.

Japan recognises Covaxin to facilitate travel from April 10: Bharat Biotech

April 08, 2022 3:53 pm

Various countries, including Australia, have already recognised Covaxin for facilitating travel

Bharat Biotech may need at least 6 months to address deficiencies

April 05, 2022 9:26 am

On Saturday, the WHO had suspended the procurement of Covaxin by UN agencies, asking Bharat Biotech for facility upgrade to address the identified GMP deficiencies. The WHO, however, had highlighted that Covaxin is effective and no safety concern exists.

No impact of WHO action on Covaxin, have not supplied to any UN agency: Bharat Biotech

April 04, 2022 8:59 pm

Covaxin has received emergency use approvals from over 25 countries.

Bharat Biotech to slow down Covaxin production

April 02, 2022 12:38 am

Covaxin is the second most commonly used Covid-19 vaccine in India and the only one being administered to those between ages 15 and 17 years under the government’s programme.

Bharat Biotech’s intranasal Covid booster dose trials get DCGI nod

January 28, 2022 3:39 pm

The approval comes soon after Covaxin and Serum Institute of India's Covishield were cleared for sale in the market.

Covaxin booster dose: Trial indicates long-term safety against infection with no serious adverse effects

January 09, 2022 3:40 am

Six months after the second Covaxin dose, a study using the vaccine as a booster dose has detected neutralising, T and B cell responses. This suggests good immune memory responses and long-term protection from severe disease, an official statement from Bharat Biotech said.